Treatment Resistant Depression Clinical Trial
Official title:
D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression
This is a two-stage experiment; the first stage is an open label trial in which participants receive six intravenous (IV) treatments of ketamine. The second stage includes participants that responded to ketamine (i.e. reduction of 25% in their symptoms of depression, as measured by the Montgomery Asberg Depression Scale MADRS). The second stage is a double-blind, controlled clinical trial of D-cycloserine (DCS) vs. placebo, as maintenance treatment in patients who responded to ketamine treatment. The aim of the study is to determine whether 8 weeks of DCS maintenance therapy will prevent relapse of depressive symptoms following ketamine infusions
Background MDD is one of the leading causes of disability worldwide [5]. A substantial
proportion of patients do not achieve adequate remission despite multiple antidepressant
trials and augmentation strategies. TRD is defined as an insufficient response to at least
two adequate antidepressant trials. Many of these patients are referred to somatic
treatment; e.g. electroconvulsive therapy (ECT), repetitive Transcranial Magnetic
Stimulation (rTMS) and Vagal Nerve Stimulation (VNS), all of which can cause side effects,
and are not always efficacious.
Ketamine has been safely used for decades for the induction and maintenance of anesthesia
and more recently for chronic pain. Ketamine is a noncompetitive, high-affinity antagonist
of the NMDA type glutamate receptor, with additional effects on dopamine and μ-opioid
receptors. During the last decade, 4 meta analyses summarizing over 22 controlled trials
have been published, showing the rapid and impressive effect of ketamine in TRD patients
[6-8]. These trials show that a single slow IV ketamine sub-anesthetic dose (0.5 mg/kg) over
40 minutes dramatically improves depressive symptoms. Across studies, a clinically
significant antidepressant response was maintained for up to 72 hours in approximately half
of the patients; only a minority had relapsed within the first two weeks post-ketamine
infusion [9, 10]. aan het Rot et al. [11] showed that repeated IV ketamine infusions prolong
the duration of improvement.
D-cycloserine (seromycin) is a broad spectrum antibiotic, in use for over thirty years in
the treatment of tuberculosis, DCS functions as a partial agonist at the NMDA-R glycine
site, with agonist effects predominating at low dose and antagonist effects at high dose.
Low DCS dosages, such as 50-500 mg/d have been implemented in anxiety patients for memory
and learning enhancement. Beneficial antidepressant effects have been reported when higher
dosages (500-1000 mg/day) were used [3]. DCS regimens in TRD patients suggest that high dose
DCS may indeed be beneficial in the treatment of MDD. However, a previous study using a
lower dosage (250mg/d) did not show significant difference over placebo [3]. The
antidepressant effects of DCS seem to derive from its ability to inhibit NMDA-R function,
similarly to ketamine. One recent study demonstrated a beneficial effect of DCS after
ketamine infusion in bipolar depression patients [12]. Due to the potential neurotoxicity of
ketamine in prolonged administration. Other NMDA antagonist should follow ketamine infusion
[13]. Therefore we reason that DCS post-ketamine administration will considerably reduce
relapse in TRD patients when compared to placebo.
Study Design
1. Patients will undergo 6 ketamine infusions within a 3-week period.
Intravenous ketamine will be administrated by a senior anesthesiologist and under the
supervision of a senior psychiatrist hence ensuring patient safety. We believe that
sub-anesthetic ketamine infusion will be safer and will cause fewer side effects than
ECT. The procedure will be explained in detail to each patient, and written consent
will be obtained.
After a psychiatric and medical evaluation by a senior psychiatrist and a senior
anesthesiologist, patients will be given ketamine infusion added on to their
antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be
given to the patients. Patients will be monitored by the experienced staff which
includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be
available nearby. All patients will be monitored continuously for heart rate and rhythm
and oxygen saturation, and blood pressure will be measured at 10 minutes intervals.
Heart rate variability will be measured and analyzed after ketamine treatment.
Measurements will be performed during the ketamine infusion at baseline, after 3 and 6
treatments. Depressive symptoms will be measured using Montgomery Asberg Depression
Scale (MADRS). In addition Clinical Global Severity Scale (CGI-S) and Clinical Global
Improvement (CGI-I) will be performed 2 hours after treatment. In many cases, patients
with depression also suffer from alexithymia: inappropriate identification of emotions.
Alexithymia will be measured at baseline after 3 and 6 treatments. Ketamine infusion
will be stopped in cases of a 20% or above increase in blood pressure or in heart rate
over baseline values and/ or an acute dissociative state.
Patients will be discharged to their homes at least three hours from end of infusion.
Due to the potential effect of ketamine each patient will need to be escorted to and
from the hospital by a family member or a friend.
2. For patients who will meet response criteria (MADRS≥25%) after 6 ketamine infusions,
ketamine administration (weeks 1-3: days 1-21) will be stopped and patients will start
receiving DCS or placebo titrated slowly up to 1000mg/d over the next 8 weeks [2] in
the following manner:
1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse
effect evaluation before drug elevation.
2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day
3. Week 7: Day 43-49 - 750mg/d, three pills per day
4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day
3. Pyridoxine 200-300mg/d will be prescribed for all patients at the beginning of the
study.
4. Patients who did not improve after 6 ketamine treatments will be removed from the
study.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04124341 -
PCS in Severe Treatment Resistant Depression
|
N/A | |
Recruiting |
NCT03887715 -
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
|
N/A | |
Completed |
NCT04727229 -
Stellate Ganglion Block for Major Depressive Disorder.
|
Phase 4 | |
Completed |
NCT04634669 -
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
|
Phase 2 | |
Withdrawn |
NCT03175887 -
Investigational TMS Treatment for Depression
|
N/A | |
Completed |
NCT03134066 -
Neurocognitive Features of Patients With Treatment-Resistant Depression
|
||
Active, not recruiting |
NCT01984710 -
Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S
|
N/A | |
Completed |
NCT01935115 -
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy
|
Phase 4 | |
Terminated |
NCT01687478 -
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
|
Phase 3 | |
Completed |
NCT00531726 -
Berlin Deep Brain Stimulation Depression Study
|
N/A | |
Recruiting |
NCT04041479 -
Biomarker-guided rTMS for Treatment Resistant Depression
|
Phase 3 | |
Recruiting |
NCT05870540 -
BPL-003 Efficacy and Safety in Treatment Resistant Depression
|
Phase 2 | |
Recruiting |
NCT04959253 -
Psilocybin in Depression Resistant to Standard Treatments
|
Phase 2 | |
Completed |
NCT04856124 -
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
|
||
Recruiting |
NCT03272698 -
ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression
|
Phase 4 | |
Active, not recruiting |
NCT04451135 -
CET- REM (Correlating ECT Response to EEG Markers)
|
N/A | |
Recruiting |
NCT05680220 -
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
|
N/A | |
Completed |
NCT03288675 -
Stepped Care aiTBS 2 Depression Study (Ghent)
|
N/A | |
Recruiting |
NCT06138691 -
KET-RO Plus RO DBT for Treatment Resistant Depression
|
Phase 1 | |
Terminated |
NCT02675556 -
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression
|
Phase 1 |